Aurinia Pharmaceuticals Inc

come up into conversation thanks why don't I start out with the first and maybe the third question there and ask you know max to build on the third and maybe give us commentary on the government pay side of the equation um you know the simple answer belief beyond on titration this is for those that don't know this is the EGFR dosing protocol that we have in place I guess our experience has been that it's only with a few number of weeks out there and limited access to direct information from office to office is that it's on track. So our net calcs in terms of what we think a net value per patient per year is seem to be playing out in the early weeks of the launch. So on track with what our assumptions would be my answer there, Alethea. You know, on the Ben-Lista thing, first, you can feel very comfortable that our team understands our data and understands theirs. And, you know, it's not the primary that comes up in conversation, I think. And I'd ask Max Galau to build on this from what he's hearing at the field level. You know, the primary is getting physicians to, one, identify what patient might be appropriate for Leukinus therapy. and then ensuring that they're committed to differentiating the product versus other therapies that might be available or challenging them on why they may not have a sense of urgency to lower proteinuria in these patients. So there's a big education factor in trying to change the way physicians have historically treated. So I think that's coming up more often than hey, when I'm making a treatment decision, do I use Benlysta or do I use lupinus? So let me turn it to Max and see if he can dig a little more into maybe that question and the public payer side of the equation. Max?

Yeah, thanks. Thanks, Peter, and thanks, Alethea. Yeah, Peter's spot on. You know, really what our focus is is really creating that urgency in terms of you know, bringing the patient in and starting the treatment, we're definitely seeing that, you know, there's just a large number of patients with high levels of proteinuria that are not controlled. And so it's really working through creating that urgency and explaining the value proposition of loop kinase. So, Medicaid. So, it's a great question. So, as of April 1st, we've now confirmed that 90% of Medicaid lives have coverage. So, we now are months out and the mandated Medicaid coverage is in place. And so, we've confirmed 90% of lives now having coverage.

Oh, wow. Thanks. That's awesome. Congrats again. Thanks, Alethea. Any more questions? Now I'll hop back into you. Okay. Thank you.